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Lymphoproliferative disorders are heterogeneous malignancy characterized by the expansion of a lymphoid clone more or less
diﬀerentiated. At the level of the oral cavity, the lymphoproliferative disorder can occur in various ways, most commonly as
lymphoid lesions with extranodal externalization, but sometimes, oral lesions may represent a localization of a disease spread.
With regard to the primary localizations of lymphoproliferative disorders, a careful examination of the head and neck, oral, and
oropharyngeal area is necessary in order to identify suspicious lesions, and their early detection results in a better prognosis for the
patient. Numerous complications have been described and frequently found at oral level, due to pathology or diﬀerent therapeutic
strategies. These complications require precise diagnosis and measures to oral health care. In all this, oral pathologists, as well as
dental practitioners, have a central role in the treatment and long-term monitoring of these patients.
1.Introduction
Under the name of lymphoproliferative disorders various
disease patterns are included which are characterized by the
expansion of a lymphoid clone more or less diﬀerentiated.
The application in recent times, of immunological methods
for determining the phenotype of many cell components,
together with the acquisitions of cytogenetic and molecular
biology, as well as clinical behavior, have helped to relatively
deﬁne a wide range of diseases that may present a hetero-
geneous clinical and morphological picture. In fact, the last
classiﬁcation of lymphoproliferative disorders lists 40 types
of lymphoproliferative syndromes to immunophenotype B
and 23 to immunophenotype T [1]. At the level of the
oral cavity, the lymphoproliferative disorder can occur in
various ways, most commonly as lymphoid lesions with
extranodal externalization, but sometimes, oral lesions may
represent a localization of a disease spread [2]. Under the key
research that sees lymphoproliferative disorders associated
with injury or events at the oral cavity, the present paper
proposes a comprehensive classiﬁcation as listed in Table 1
and deeply described below.
2.Classiﬁcationand RelatedAspects
of the OralPathologies Associatedwith
Lymphoproliferative Disorders
2.1. Group 1: Primary Oral Lymphoproliferative Disorders
Limited to the Oral Cavity that Will not Invade Other Body
Districts. Primary extranodal involvement can be seen in
10% to 35% of cases of non-Hodgkin lymphomas. These
locations include the gastrointestinal tract, skin, testicles,
kidneys, and bones [3, 4]; the NHL of the central nervous
system account for 1% of cases [5, 6]. Although the oral
involvement of NHL is rare, they are the second most
common oral malignant disease after oral squamous cell
carcinoma [7, 8], constituting of 2.2% of all malignancies
of the head-neck, 3.5% of intraoral malignancies, 5% of
tumors of the salivary glands, and 2.5% of all cases of
NHL [8]. Although every other site may be aﬀected, Ring
Waldayer is the most commonly involved [9]. The WHO
system classiﬁes NHL as indolent, aggressive, and highly
aggressive. Indolent lymphoma accounts for 40% af all NHL
with the most common type being follicular lymphoma;
aggressive lymphoma accounts for approximately 50% of2 Journal of Oncology
Table 1: Classiﬁcation of the oral pathologies associated with lymphoproliferative disorders (see text for details).
Group Primary disorder Localization of the primary
disorder
S e c o n d a r y( a )o ra s s o c i a t e d
(b) disorder
Localization of the
secondary or associated
disorder
1 Lymphoproliferative disorders Oral cavity None —
2 Lymphoproliferative disorders Oral cavity Lymphoproliferative
disorders (a) Other body districts
3 Lymphoproliferative disorders Other body districts Lymphoproliferative
disorders (a) Oral cavity
4 Oral lesions Oral cavity Lymphoproliferative
disorders (b) Other body districts
5 Lymphoproliferative disorders Other body districts Oral lesions (a) Oral cavity
6 Lymphoproliferative disorders Other body districts
Oral lesions secondary to
the treatment of the
primary disorder
Oral cavity
7A I D S —
AIDS-related
lymphoproliferative
disorders
Oral cavity
Oral lesions refer to all of the diseases excluding lymphoproliferative disorders.
cases and include diﬀuse large B-cell lymphoma and T-
cell natural killer (NK) cell lymphoma; highly aggressive
lymphoma includes EBV-associated Burkitt lymphoma and
lymphoblastic lymphoma [10]. Even though each type
of NHL can occur at the level of oral cavity, the most
common types are large-cell lymphoma and lymphoma of
small lymphocytes lymphoma; mucosa-associated lymphoid
tissue (MALT) lymphoma, follicular lymphoma, Burkitt’s
lymphoma, and immunocytoma, immunoblastic lymphoma
are also reported [8, 11, 12]. The most common signs and
symptoms with which the NHL will have intraoral include
tissue swelling, tooth loss, and paresthesia. The radiographic
measurements can highlight widespread osteolysis with loss
of lamina dura. Oral lesions may appear as exophytic neo-
plasms, erythematous, asymptomatic, often with superﬁcial
ulcerations secondary to chronic trauma [11]( Figure 1).
Hodgkin’s disease is a form of malignancy characterized
by proliferation of neoplastic cells (Hodgkin and Reed-
Sternberg cells) associated with a polymorphic cellular com-
ponent (lymphocytes, histiocytes, eosinophils, neutrophils,
and plasma cells), considered to be reactive [13]. From its
initial description until the 1990s, the nature and lineage of
the Reed-Sternberg cell and the inﬂammatory inﬁltrate that
compromisesHodgkindiseaseweredebated.Theapplication
ofPCRtechniquerevealedthatHodgkinandReed-Sternberg
cells were clonal B cells in 98% of the patients, leading to the
change of the designation of Hodgkin disease into Hodgkin
lymphoma (LH) in the WHO classiﬁcation of lymphoid
neoplasms [1]. Primary oral and oropharyngeal lesions are
rare [14]. Since the Waldayer ring is commonly involved by
NHL that sometimes shows cells of Reed-Sternberg cell-like,
the diagnosis of LH is diﬃcult, especially when there are
only small biopsy specimens [15,16]. The most commonsite
involved is the ring of Waldayer followed by the lips [17],
tongue base [18, 19], buccal mucosa [20, 21], and parotid
gland [22, 23].
The oral manifestations by plasma cell tumors can
occur in three diﬀerent ways: as a consequence of the local
manifestation of multiple myeloma, bone plasmacytoma
as solitary, or as extramedullary plasmacytoma [24]. The
primary manifestations of plasma cell neoplasms at the
oral level are represented by solitary and extramedullary
plasmacytoma.
The Plasmacytoma of bone can be considered a localized
solitary myeloma (Figure 2). Solitary bone plasmacytoma
is a malignant monoclonal gammopathy [25, 26]; it is a
plasma cell cancer that occurs as a single osteolytic lesion
without plasmacytosis of the bone marrow and that is
capable of secreting monoclonal M protein [27, 28]. This
disease accounts for 10% of all plasma cell tumors and can
strike[25,27,28],althoughrarely,intheoralcavity,showing
a predilection for the mandibular retromolar area [29]; its
radiological appearance may have one of two patterns, as
either an oval-shaped lytic image with destruction of the
cortical bone, or as a hyperinsuﬄating lesion showing a
convex bicortical bone [30].
Instead, the extramedullary plasmacytoma is a plasma
celltumorlocatedseparatelyfromthebonemarrow[31];itis
foundinallpartsofthebodywherethislymphoidtissue[32–
38], in 90% of the extramedullary plasmacytoma, is present
in the head and neck. Clinically [39–41], the plasmacytoma
extraosseous is present as a sessile or pedunculated exophytic
neoformation, circumscribed or inﬁltrative, ranging in color
from red-purple to gray or yellow-white [42–50].
2.2. Groups 2: Primary Oral Lymphoproliferative Disorders
t h a tM a yE v e n t u a l l yI n v a d eO t h e rB o d yD i s t r i c t s .The oral
manifestations of multiple myeloma (MM), a disease char-
acterized by the proliferation and accumulation in the
bone marrow of a clone of plasma cells to produce a
homogeneous monoclonal protein [13, 30, 51, 52], are
extensively reported in the literature; the oral manifestationsJournal of Oncology 3
Figure 1: Primary extranodal non-Hodgkin lymphoma: painless
mass involving the left palate.
Figure 2: Plasmacytoma: axial noncontrast CT image at the
level of left maxillary sinus demonstrates an expansile, destructive
intraosseous lesion involving the left maxillary sinus.
are the initial sign of submission in 12% to 15% of cases
of MM [53–55]. The oral features include facial, oral,
and dental pain, numbness and paresthesia, swelling, soft
tissue neoplasms [56], tooth mobility, bleeding, and deposit
of amyloid substance especially on the tongue [57–60].
Other examples of oral lesions as ﬁrst manifestation of
lymphoproliferative disorders may be the inﬁltration of the
oral mucosa by a B-cell chronic lymphocytic leukemia [61],
the lymphomatous papulosis, a condition mucocutaneous
applicant, self-limited, characterized by papular eruptions
[62], and Mycosis fungoides, T-cell cutaneous lymphoma in
which the involvement of the oral cavity is a rare event but
well documented [63, 64].
2.3. Group 3: Primary Systemic Lymphoproliferative Disorders
T h a tM a yE v e n t u a l l yI n v a d eO r a lC a v i t y .In addition to
entering into this category, the previously treated lympho-
proliferative disorders, where the diagnosis of oral lymphoid
malignancy was subsequent to an indication of their early
sign, mentioned in this regard a clinical-pathological entity
of which we have evidence in the literature for over a
century of mycosis fungoides (MF), chronic lymphoprolif-
erative disorder with predominantly cutaneous involvement
characterized by the proliferation of T lymphocytes that in
Figure3:Paraneoplasticpemphigus:multipleerosionsaﬀectingthe
marginal gingival.
advanced stages of the disease can accumulate also in lym-
phoid organs, bone marrow, and peripheral blood (Sezary
Syndrome) [13]. Involvement in oral MF is an occasional
ﬁnding observed from 7.4% to 18% of patients undergoing
necropsy [65, 66]. Despite these ﬁndings relatively frequent
mucosal involvement in vivo is a rare event; there is no
predisposition to sex; age of onset varies from 36 to 81
years, with an average of 61 years. Oral sites most frequently
involved are the tongue, palate, gingiva, buccal mucosa, lips,
and oropharynx. In almost all patients, the lesions skin prior
to the mucosa over a period of time ranging from 7 months
to 40 years [67].
2.4. Groups 4: Primary Oral Lesions (Excluding Lymphopro-
liferative Disorders) That Are Associated with Systemic Lym-
phoproliferative Disorders, That Is, Paraneoplastic Pemphigus.
Here is a list of non-speciﬁc signs and symptoms present
in association with lymphoproliferative disorders of the oral
cavity:lymphadenopathy,trismus,erythema,epiphora,pain,
swelling, facial asymmetry or swelling of buccal mucosa,
sinusitis, increased lacrimation and abscesses of the lacrimal
sac, diplopia, nasal obstructions, sepsis, fever, runny nose,
prosthetic instability, headache, and paresthesia idiopathic
epistaxis. Suspicion of malignancy usually develops only
after these inﬂammatory symptoms have not responded
to conventional treatment protocols, upon which more
accurate evaluations are required. Although oral lymphomas
are extremely rare [68, 69], they can occur earlier and
be placed in the diﬀerential diagnosis with non-speciﬁc
inﬂammatory processes. Moreover, the early recognition of
these subtle cancers can decrease their morbidity [70].
Paraneoplastic pemphigus (PNP), or paraneoplastic
autoimmune multiorgan syndrome is a rare autoimmune
vesiculobullous disease ﬁrst described by Anhalt et al. in
1990 in patients with occult malignancies [71, 72]. The
PNP may have mucocutaneous and systemic manifestations.
Erosive eye lesions, sinuses, oral cavity, the gastrointestinal
system, and respiratory and genital epithelium could aﬀect
them. Clinically, lesions may occur as polymorphic, such
as pemphigus, bullous pemphigoid, erythema multiforme,
the graft-versus-host disease, and lichen planus [73–75]
(Figure 3).
Dermatomyositis (DM) is a rare inﬂammatory microan-
giopathic disease that aﬀects skeletal muscles, with clinical
externalization as characteristics mucocutaneous manifesta-
tions.4 Journal of Oncology
Figure 4: Thrombocytopenia: traumatic hematoma of the soft
palate.
Oral lesions in paraneoplastic DM (leucoerythroplasia
and ulcerative lesions) have rarely been described in the lit-
erature [76–79]. The DM is totally resolved if the underlying
disease is treated and the resurgence of DM expresses relapse
of malignancy [76, 79].
In the literature, there are reports of a single case of
multiple myeloma with ﬁrst manifestation at the oral level
under the clinical aspects of lichen planus, showing extensive
and irregular erosions present at buccal mucosa, labial,
palatal mucosa, and ventral tongue [80].
2.5. Group 5: Primary Lymphoproliferative Disorders That
May Eventually Invade Oral Cavity Yielding Lesions (Exclud-
ing Lymphoproliferative Disorders). The literature contains
many works that correlate the paraneoplastic pemphigus
(PNP), a rare autoimmune vesiculobullous disease underly-
ing a malignancy [71, 72], with typical oral lesions of lichen
planus [81] or lichenoid reactions [82]. In the literature
there are numerous works reported that associate mucous
membrane pemphigoid (MMP) with malignancies, including
lung cancer [83], pancreatic adenocarcinoma [84], gastric
adenocarcinoma [85], and squamous cell carcinoma of the
conjunctiva [86] there are only two cases reported of MMP
with oral manifestations associated to lymphoproliferative
d i s o r d e r s :aB - c e l ll y m p h o m a[ 87] and chronic lymphocytic
leukemia [88]. It has been described in the literature that
large amount of cases have connection between bullous
pemphigoid (BP) and lymphoproliferative disorders such as
chronic lymphocytic leukemia [89–91] and lymphoblastic
lymphoma [92].
Necrotizing oral processes, although rare in the gen-
eral population, can rapidly evolve in devastating stages
in immunocompromised patients [93–96]a n da r eo f t e n
associated with periodontal disease. These are patients with
lymphoproliferative disorders such as acute lymphoblastic
leukemia, which developed necrotic processes at the level of
the oral cavity not associated with typical ulcer-necrotizing
periodontal diseases, but by bacteria in the oral cavity
unusually found as Pseudomonas aeruginosa. Patients with
impaired lymphocyte function or reduced counts of neu-
trophils, due to lymphoproliferative disorders, have led to
the acquisition of new infections and/or exacerbation or
reactivation of latent infection (periapical periodontitis and
herpes simplex). In many cases the clinical presentation of
oral infections may be atypical when compared to those
normally seen in healthy patients.
The origin of odontogenous infection of the pulp and
periodontal is frequently observed in patients with lym-
phoproliferative disorders and should be suspected when
orofacialpain,extensivedentalrestorations,anddentalcaries
and periapical radiopacity occur [97, 98].
Oropharyngeal candidiasis is the most common fungal
infection in cancer patients [99–101]. The candidiasis may
present as pseudomembranous candidiasis, erythematous,
hyperplastic, or angular cheilitis. The symptoms include
general discomfort, dysgeusia, xerostomia, and mouth burn.
Deep fungal infections should be suspected in patients with
solitary ulcer that does not retreat. This group includes
infections such as aspergillosis, histoplasmosis, and that by
Zygomycetes,andthetreatmentrequiresaggressivetreatment
with intravenous azoles, amphotericin B, and echinocandins
[102].
Primary infection or reactivation of herpes viruses is
common in patients with lymphoproliferative disorders
especiallyduringtheadvancedstagesofthedisease.Infection
with herpes simplex is most common in these patients; the
reactivation of the Varicella-Zoster virus (VZV) is less com-
mon [103]. Epstein-Barr virus infection (EBV) is associated
with oral hairy leucoplakia, a very rare whitish lesion that
occurs on the lingual lateral margins in myelosuppressive
patients[104,105].InfectionbyCytomegalovirus (CMV)can
occur on any intraoral mucosal surface in the form of an
ulcer-free character of speciﬁcity, which persists for weeks or
months.
Because of thrombocytopenia in the course of lym-
phoproliferative disorders, intraoral bleeding is commonly
observed, which is present with petechiae, bruising, and
occasionally with the formation of hematomas (Figure 4).
2.6. Group 6: Oral Complications Due to Systemic Treatment
for Lymphoproliferative Disorders (i.e., Chemotherapy,
Radiotherapy, Autologous, or Allogeneic Bone
Marrow Transplant)
Chemotherapy and Radiotherapy. In addition to what is
included in this paper the oral infectious complications
(bacterial, fungal, viral), previously treated on immuno-
suppression induced by lymphoproliferative disorder, and
here remembered as a possible consequence of drug-induced
immunodeﬁciency, we will consider the common charac-
teristic found in the course of oncohaematology treatment
regimens. Patients with lymphoproliferative disorders who
are treated with high doses of radiotherapy at the head
and neck level, associated with aggressive chemotherapy
regimens, are at greatest risk of developing oropharyngeal
mucositis. Xerostomia is often present in patients with
lymphoproliferative disorders treated with radiotherapy in
theheadandneckregionduetodamageofthemajorsalivary
glands, which are still included in the irradiation of tumors.
As another long-term complication of radiation therapy
for head and neck lymphomas in patients who underwent
radiotherapy, we noticed the osteoradionecrotic maxillary
bone as a result of permanent damage of the capillary bed
of bone and osteocytes caused by radiation.Journal of Oncology 5
Figure 5: Oral cGVHD: ulceration of the buccal mucosa.
Autologous Transplantation. Oral complications are obser-
ved in 85% of cases of patients after autologous bone
marrow transplantation (ABMT). These complications are
due to the eﬀects derived from antiblastic chemotherapy and
radiotherapy. Infections occur during the period of severe
marrow aplasia and may be secondary to the conditions of
the oral cavity before the transplant. Patients treated for
lymphoproliferative disorders are at increased risk of relapse
of the primary disease so as to develop subsequent tumors
both hematologic [106] and nonhematologic in this regard
we consider the oral squamous cell carcinoma as a second
primary solid tumor after allogeneic transplant [107].
A variety of circulating autoantibodies can be found
from 20% to 61% of patients undergoing autologous bone
marrow transplant [108–111], and a number of these
patients may demonstrate autoantibody-mediated diseases
such as myasthenia gravis and autoimmune cytopenias [112]
and some cases of oral diseases, such as oral vesiculobullous
(pemphigus and pemphigoid) [113–116].
The Graft-versus-host disease (GVHD) is a multisys-
tem immunologic reaction resulting from the action of
immunocompetent cells transplanted from a donor to an
immunodeﬁcient host [117]. The recipients of allogeneic
hematopoietic cell transplantation (allo-HTC) are at greater
risk of developing the disease from acute and chronic
graft versus host. The likelihood of developing GVHD
depends on the type of conditioning regimen (ablative vs.
totally reduced intensity regimens). GVHD in oral lesions,
although infrequent, can be observed, and rarely require
speciﬁc treatment. Chronic GVHD typically develops after
the hundredth day, with an incidence ranging from 25% to
40% after allo-HCT [107, 117]( Figure 5). The mouth is one
of the locations most commonly aﬀe c t e db ye v e n t ss u c ha s
lichenoid mucositis (including ulcers), pain, odynophagia,
dysgeusia,hypofunctionofthesalivaryglands,cariesdecayed
teeth, and rarely sclerotic processes that lead to a hypomobil-
ity and a reduction in functionality [10, 118].
Supportive Therapy. Bisphosphonates are drugs used in
combination with chemotherapy in the treatment of hyper-
calcemia secondary to malignancy, lytic bone metastases
and multiple myeloma [119–121]. Starting from 2003, an
increasing number of cases that describe the correlation
between osteonecrosis of the jaw (ONJ) and administration
of intravenous bisphosphonates were published in the litera-
ture [122–131]( Figure 6).
Figure 6: Bisphosphonates-related osteonecrosis of the jaw. Spon-
t a n e o u sn e c r o t i cb o n ee x p o s u r e .
2.7. Group 7: AIDS-Related Lymphoproliferative Disorders of
the Oral Cavity. Approximately 10% of all cases of non-
Hodgkin lymphomas in the United States and Europe
are AIDS related [132–134]. Typically, AIDS-related NHL
has a predilection for extranodal sites and appears in the
head and neck, in 50-60% of cases [135–144]; they have
an aggressive course and a poor prognosis [145–147]. In
histopathology these lymphomas are B-cells derived and
characterized by widespread growth, pleomorphism, high-
grade morphology, frequent mitotic ﬁgures, and increased
tendency to develop into necrosis [148–153]. Lymphomas
of head and neck may involve the gingiva, palate, tongue,
tonsils, nasopharynx, orbits, parotid glands, jaw breasts,
soft tissues, and hypopharynx. These tumors are associated
with severe immunosuppression and a poor response to
chemotherapy.
3. Conclusions
Lymphoidneoplasmsareheterogeneousmalignantdisorders
of the lymphatic system characterized by uncontrolled
proliferation of lymphoid cells or their precursors. With
regard to the primary localizations of lymphoproliferative
disorders, a careful examination of the head and neck, oral,
and oropharyngeal area is necessary in order to identify sus-
picious lesions and their early detection. An early diagnosis
mayallowtreatmentatearlystagesofthedisease,resultingin
a better prognosis for the patient. Numerous complications
have been described and frequently found at oral level,
due to pathology or diﬀerent therapeutic strategies. These
complications require a precise diagnosis and measures to
oralhealthcare.Furthermore,theevaluationofpatientsafter
treatmentforlymphomaisessentialtopreventrelapseandto
recognize early any eventual secondary localizations.
In all this, oral pathologists, as well as dental practi-
tioners, have a central role in the treatment and long term
monitoring of these patients, having the opportunity and the
dutytoexamineandmakeadiagnosisatthelevelofhardand
soft tissue of the oral cavity.
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